Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ProShares Ultra Bitcoin ETF (BITU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ProShares Ultra Bitcoin ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while ProShares Ultra Bitcoin ETF trades at $8.91. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | BITU | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $64.41 |
52-Week Low | $20.06 | $8.12 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BITU trades at $9.48, up 7.36% in the last 24 hours, with a bullish technical signal but bearish moving averages. The stock faces structural challenges as a leveraged ETF, with key financial ratios like P/E and P/S unavailable. Recent news highlights underperformance relative to Bitcoin due to daily rebalancing decay, with Seeking Alpha rating it a Hold on June 16, 2026.
Outlook remains cautious due to BITU's leveraged structure and volatility decay risks. Investment opportunities are limited to short-term tactical plays during clear bull markets, but long-term holders face significant erosion. Primary risks include ETF mechanics, Bitcoin price dependency, and investor sentiment shifts amid crypto volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →
